School of Medicine, Chongqing University, Chongqing, 400030, China.
Department of Hematology-Oncology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, 400030, China.
Cell Commun Signal. 2024 Jun 19;22(1):337. doi: 10.1186/s12964-024-01714-7.
Killer cell lectin-like receptor G1 (KLRG1) is an immune checkpoint receptor expressed predominantly in NK and T-cell subsets that downregulates the activation and proliferation of immune cells and participates in cell-mediated immune responses. Accumulating evidence has demonstrated the importance of KLRG1 as a noteworthy disease marker and therapeutic target that can influence disease onset, progression, and prognosis. Blocking KLRG1 has been shown to effectively mitigate the effects of downregulation in various mouse tumor models, including solid tumors and hematologic malignancies. However, KLRG1 inhibitors have not yet been approved for human use, and the understanding of KLRG1 expression and its mechanism of action in various diseases remains incomplete. In this review, we explore alterations in the distribution, structure, and signaling pathways of KLRG1 in immune cells and summarize its expression patterns and roles in the development and progression of autoimmune diseases, infectious diseases, and cancers. Additionally, we discuss the potential applications of KLRG1 as a tool for tumor immunotherapy.
杀伤细胞凝集素样受体 G1（KLRG1）是一种主要表达在 NK 和 T 细胞亚群中的免疫检查点受体，它下调免疫细胞的激活和增殖，并参与细胞介导的免疫反应。越来越多的证据表明，KLRG1 作为一个重要的疾病标志物和治疗靶点具有重要意义，它可以影响疾病的发生、发展和预后。阻断 KLRG1 已被证明可在各种小鼠肿瘤模型中有效减轻下调的影响，包括实体瘤和血液恶性肿瘤。然而，KLRG1 抑制剂尚未被批准用于人类，并且对 KLRG1 在各种疾病中的表达及其作用机制的理解仍不完整。在这篇综述中，我们探讨了 KLRG1 在免疫细胞中的分布、结构和信号通路的改变，并总结了其在自身免疫性疾病、传染病和癌症的发生和发展中的表达模式和作用。此外，我们还讨论了 KLRG1 作为肿瘤免疫治疗工具的潜在应用。
